Rhumbline Advisers Cuts Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE)

Rhumbline Advisers reduced its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 94.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,176 shares of the biotechnology company’s stock after selling 256,914 shares during the period. Rhumbline Advisers owned 0.15% of bluebird bio worth $118,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in bluebird bio by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after buying an additional 166,771 shares in the last quarter. State Street Corp grew its position in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares in the last quarter. FMR LLC grew its position in shares of bluebird bio by 8.1% in the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after purchasing an additional 186,903 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares in the last quarter. Finally, Barclays PLC grew its position in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares in the last quarter. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Stock Down 1.5 %

NASDAQ:BLUE opened at $3.94 on Tuesday. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The stock’s fifty day moving average is $6.85 and its two-hundred day moving average is $8.51. bluebird bio, Inc. has a 52 week low of $3.56 and a 52 week high of $33.20. The stock has a market capitalization of $38.30 million, a price-to-earnings ratio of -0.11 and a beta of 0.76.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. StockNews.com assumed coverage on bluebird bio in a research report on Tuesday, March 4th. They issued a “sell” rating for the company. Barclays upped their price target on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. Bank of America lowered bluebird bio from a “buy” rating to a “neutral” rating and dropped their price target for the company from $60.00 to $10.00 in a research report on Friday, November 15th. Finally, Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $48.10.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.